What's Happening?
Stealth BioTherapeutics has completed enrollment in its Phase 1 dose escalation trial for bevemipretide eye drops, aimed at treating dry age-related macular degeneration (AMD). The trial evaluated the safety, tolerability, and pharmacokinetics of the eye drops, with
preliminary results to be presented at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting. Bevemipretide is a mitochondrial-targeted therapeutic candidate designed to offer a noninvasive treatment option for dry AMD. The completion of this trial marks a significant milestone in the development of bevemipretide, with plans to initiate a Phase 2 trial later in 2026.
Why It's Important?
The development of bevemipretide eye drops represents a potential breakthrough in the treatment of dry AMD, a leading cause of blindness among older adults. The noninvasive nature of the eye drops could improve patient adherence and outcomes, addressing a significant unmet need in ophthalmic care. The successful completion of the Phase 1 trial is a critical step toward advancing bevemipretide to further clinical trials, which could ultimately lead to a new treatment option for millions of individuals affected by dry AMD.
What's Next?
Stealth BioTherapeutics plans to present the preliminary results of the Phase 1 trial at the upcoming ARVO Annual Meeting. The company is also preparing to initiate a Phase 2 trial for bevemipretide eye drops in late 2026. This next phase will further evaluate the efficacy and safety of the treatment in a larger patient population. The outcomes of these trials will be crucial in determining the future of bevemipretide as a viable treatment for dry AMD, with potential implications for regulatory approval and commercialization.
